PROCESS FOR PRODUCING GLYCOPEPTIDES
1476422 Immunostimulating glycopeptide WELLCOME FOUNDATION Ltd 23 May 1974 [23 Feb 1973 14 Feb 1974] 9149/73 and 6759/74 Heading A5B [Also in Division C3] An immunostimulating glycopeptide capable of conferring on mammals and birds a resistance to tumours and pathogens is obtained from cell wall mat...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English Hungarian |
Published |
28.07.1979
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 1476422 Immunostimulating glycopeptide WELLCOME FOUNDATION Ltd 23 May 1974 [23 Feb 1973 14 Feb 1974] 9149/73 and 6759/74 Heading A5B [Also in Division C3] An immunostimulating glycopeptide capable of conferring on mammals and birds a resistance to tumours and pathogens is obtained from cell wall material of an immunostimulating bacterium of the Actinomycetaceae Family of Prevots classification. Bacteria specified include Corynebacterium parvum, C. anaerobium, C. granulosum, C. liquifaciens, C. pyogenes, C. lymphophilum, C. hepatodystrophicans, C. adamsoni, C. avidium, C. diphtheroides, C. renale cuniculi, C. acnes, C. equi and C. ovis. The glycopeptide is extracted by (a) culturing the bacteria, (b) harvesting the cells and (c) treating the cells with a biphasic extraction solvent comprising water and a phenol so as to yield the glycopeptide as an insoluble residue. The cells are generally subjected to lysis before extraction with the biphasic solvent. The glycopeptide may be recovered by centrifugation. The product is substantially insoluble in water, saline, methanol, ethanol, phenol, chloroform, dioxan, pyridine, dimethylformamide, diethylene glycol and hexane, has infra-red peptide absorption at 1550 and 1660 cm-1, infra-red carbohydrate absorption between 950 and 1100 cm-1 with peak between 1050 and 1070 cm-1, has substantially no infra-red lipid absorption between 2850 and 2950 cm-1 and after intravenous administration increases the liver and spleen weight of mice and increases the life expectancy of mice with tumours. The glycopeptide is combined with a carrier for use. |
---|---|
Bibliography: | Application Number: HU1974WE00501 |